|
1
|
Picci P, Manfrini M, Fabbri N, Gambarotti
M and Vanel D: Synovial sarcoma In: Atlas of Musculoskeletal Tumors
and Tumor like Lesions. Springer; International Publishing, Cham;
pp. 359–364. 2014
|
|
2
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Furusato B, Mohamed A, Uhlén M and Rhim
JS: CXCR4 and cancer. Pathol Int. 60:497–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim J, Mori T, Chen SL, Amersi FF,
Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, et al:
Chemokine receptor CXCR4 expression in patients with melanoma and
colorectal cancer liver metastases and the association with disease
outcome. Ann Surg. 244:113–120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Müller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koshiba T, Hosotani R, Miyamoto Y, Ida J,
Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, et
al: Expression of stromal cell-derived factor 1 and CXCR4 ligand
receptor system in pancreatic cancer: A possible role for tumor
progression. Clin Cancer Res. 6:3530–3535. 2000.PubMed/NCBI
|
|
7
|
Schimanski CC, Schwald S, Simiantonaki N,
Jayasinghe C, Gönner U, Wilsberg V, Junginger T, Berger MR, Galle
PR and Moehler M: Effect of chemokine receptors CXCR4 and CCR7 on
the metastatic behavior of human colorectal cancer. Clin Cancer
Res. 11:1743–1750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeelenberg IS, Ruuls-Van Stalle L and Roos
E: The chemokine receptor CXCR4 is required for outgrowth of colon
carcinoma micrometastases. Cancer Res. 63:3833–3839.
2003.PubMed/NCBI
|
|
9
|
Kim RH, Li BD and Chu QD: The role of
chemokine receptor CXCR4 in the biologic behavior of human soft
tissue sarcoma. Sarcoma. 2011.593708:2011.
|
|
10
|
Li YJ, Dai YL, Zhang WB, Li SJ and Tu CQ:
Clinicopathological and prognostic significance of chemokine
receptor CXCR4 in patients with bone and soft tissue sarcoma: A
meta-analysis. Clin Exp Med. 17:59–69. 2017. View Article : Google Scholar
|
|
11
|
Palmerini E, Benassi MS, Quattrini I,
Pazzaglia L, Donati D, Benini S, Gamberi G, Gambarotti M, Picci P
and Ferrari S: Prognostic and predictive role of CXCR4, IGF-1R and
Ezrin expression in localized synovial sarcoma: is chemotaxis
important to tumor response. Orphanet J Rare Dis. 10:62015.
View Article : Google Scholar
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Subramanian S, Lui WO, Lee CH, Espinosa I,
Nielsen TO, Heinrich MC, Corless CL, Fire AZ and van de Rijn M:
MicroRNA expression signature of human sarcomas. Oncogene.
27:2015–2026. 2008. View Article : Google Scholar
|
|
15
|
Fujiwara T, Kunisada T, Takeda K and Ozaki
T: MicroRNAs and soft tissue sarcomas. Adv Exp Med Biol.
889:179–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q,
Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to
suppress the proliferation, invasion, and migration of prostate
cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song L, Liu D, Wang B, He J, Zhang S, Dai
Z, Ma X and Wang X: miR-494 suppresses the progression of breast
cancer in vitro by targeting CXCR4 through the Wnt/β-catenin
signaling pathway. Oncol Rep. 34:525–531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Wang L, Liu Z, Zu C, Xing F, Yang P,
Yang Y, Dang X and Wang K: MicroRNA-494 inhibits cell proliferation
and invasion of chondrosarcoma cells in vivo and in vitro by
directly targeting SOX9. Oncotarget. 6:26216–26229. 2015.PubMed/NCBI
|
|
19
|
Zhi X, Wu K, Yu D, Wang Y, Yu Y, Yan P and
Lv G: MicroRNA-494 inhibits proliferation and metastasis of
osteosarcoma through repressing insulin receptor substrate-1. Am J
Transl Res. 8:3439–3447. 2016.PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
21
|
Krieg AH, Hefti F, Speth BM, Jundt G,
Guillou L, Exner UG, von Hochstetter AR, Cserhati MD, Fuchs B,
Mouhsine E, et al: Synovial sarcomas usually metastasize after
>5 years: A multi-center retrospective analysis with minimum
follow-up of 10 years for survivors. Ann Oncol. 22:458–467. 2011.
View Article : Google Scholar
|
|
22
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al EORTC Soft Tissue and Bone Sarcoma Group: PALETTE
study group: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oda Y, Tateishi N, Matono H, Matsuura S,
Yamamaoto H, Tamiya S, Yokoyama R, Matsuda S, Iwamoto Y and
Tsuneyoshi M: Chemokine receptor CXCR4 expression is correlated
with VEGF expression and poor survival in soft-tissue sarcoma. Int
J Cancer. 124:1852–1859. 2009. View Article : Google Scholar
|
|
25
|
Yu PY, Balkhi MY, Ladner KJ, Alder H, Yu
L, Mo X, Kraybill WG, Guttridge DC and Iwenofu OH: A selective
screening platform reveals unique global expression patterns of
microRNAs in a cohort of human soft-tissue sarcomas. Lab Invest.
96:481–491. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Salati S, Salvestrini V, Carretta C,
Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E,
Barbieri G, et al: Deregulated expression of miR-29a-3p miR-494-3p
and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in
CML leukemic stem cells. Oncotarget. 8:49451–49469. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jones KB, Su L, Jin H, Lenz C, Randall RL,
Underhill TM, Nielsen TO, Sharma S and Capecchi MR: SS18–SSX2 and
the mitochondrial apoptosis pathway in mouse and human synovial
sarcomas. Oncogene. 32:2365–2371. 2013. View Article : Google Scholar
|
|
28
|
Joyner DE, Albritton KH, Bastar JD and
Randall RL: G3139 antisense oligonucleotide directed against
antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the
FU-SY-1 synovial sarcoma cell line. J Orthop Res. 24:474–480. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao X, Zhou Y, Chen YU and Yu F: miR-494
inhibits ovarian cancer cell proliferation and promotes apoptosis
by targeting FGFR2. Oncol Lett. 11:4245–4251. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z
and Liu Y: miR-494 promotes cell proliferation, migration and
invasion, and increased sorafenib resistance in hepatocellular
carcinoma by targeting PTEN. Oncol Rep. 34:1003–1010. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Macedo T, Silva-Oliveira RJ, Silva VAO,
Vidal DO, Evangelista AF and Marques MMC: Overexpression of mir-183
and mir-494 promotes proliferation and migration in human breast
cancer cell lines. Oncol Lett. 14:1054–1060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Faversani A, Amatori S, Augello C, Colombo
F, Porretti L, Fanelli M, Ferrero S, Palleschi A, Pelicci PG,
Belloni E, et al: miR-494-3p is a novel tumor driver of lung
carcinogenesis. Oncotarget. 8:7231–7247. 2017. View Article : Google Scholar :
|
|
33
|
Zhao XQ, Liang TJ and Fu JW: miR-494
inhibits invasion and proliferation of gastric cancer by targeting
IGF-1R. Eur Rev Med Pharmacol Sci. 20:3818–3824. 2016.PubMed/NCBI
|
